Publication Topic

Borghoff SJ, Heintz MM, Rivera BN, Haws L, Thompson C. 2025. Evaluation of an anti-thyroid mode of action for thyroid follicular cell adenomas in female mice exposed to tertiary butyl alcohol. Regul Toxicol Pharmacol 105936;  doi: 10.1016/j.yrtph.2025.105936. Online ahead of print Sept. 4, 2025. PMID: 40914479.

Heintz MM, Buerger AN, Haws LC, Cullen JM, East AW, Thompson CM. 2025. Comparison of phenotypic and transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in wild-type and Pparα-null mouse livers. Toxicol Sci 206(1):183-201; doi: 10.1093/toxsci/kfaf049. PMID: 40216583.

Cook B, Nelms MD, Harris D, Bever RJ, Lynn SC, Borghoff S, et al. Clustering chemicals for predicting behavior and hazards: Insights from the endocrine disruptor screening program (EDSP) universe of chemicals. American Society of Cellular and Computational Toxicology Annual Meeting, Research Triangle Park, NC, October 2024.

Vincent M, Fitch S, Bylsma L, Thompson C, Rogers S, Britt J, Wikoff D. Integration of toxicological and epidemiological information to evaluate biological plausibility and causality of associations between inhaled formaldehyde (FA) and lymphohematopoietic (LHP) cancers. Abstract 5157, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024. 

Heintz MM, Haws LC, Klaunig JE, Cullen JM, Thompson CM. 2023. Assessment of the mode of action underlying development of liver lesions in mice following oral exposure to HFPO-DA and relevance to humans. Toxicol Sci 192(1):15–29; doi: 10.1093/toxic/kfad004. PMID: 36629480.

Thompson CM, Wikoff DS, Proctor DM, Harris MA. An evaluation of risk assessments on hexavalent chromium [Cr(VI)]: The past, present, and future of mode of action research. Poster presented at Society of Toxicology 62^nd Annual Meeting, Nashville, TN, March 2023.

Thompson CM, Chappell GA, Mittal L, Gorman B, Proctor DM, Haws LC, Harris MA. Use of targeted mode-of-action research to inform human health risk assessment of hexavalent chromium. Poster presented at Society of Toxicology Annual Meeting, San Diego, CA, March 2022.

Borghoff SJ, Fitch SE, Black MVB, McMullen PD, Andersen ME, Chappell GA. 2021. A systematic approach to evaluate plausible modes of [action] for mouse lung tumors in mice exposed to 4-methylimidozole. Regul Toxicol Pharmacol 124(Aug):104977; doi: 10.1016/j.yrtph.2021.104977. PMID: 34174380.

Guo X, Seo JE, Petibone D, Tryndyak V, Lee UJ, Zhou T, Robison TW, Mei N. 2020. Performance of HepaRG and HepG2 cells in the high-throughput micronucleus assay for in vitro genotoxicity assessment. J Toxicol Environ Health A 83(21-22):702-717; doi: 10.1080/15287394.2020.1822972.

Thompson CM, Gentry R. An updated mode-of-action analysis for formaldehyde-induced nasal tumors in rodents: A case study using the IPCS MOA and human relevance frameworks. Poster at Society of Toxicology 58th Annual Meeting, Baltimore, MD, March 2019.

Borghoff S, Wikoff D, Urban JD, Rager JE. A systematic approach to identify plausible mode-of-actions (MOA) for an increased incidence of lung tumors in mice with chronic exposure to 4-methylimidazole (4-MEI). Society of Toxicology 57th Annual Meeting, San Antonio, TX, March 2018.

Thompson CM, Suh M, Proctor DM, Harris MA. Ten factors for considering the mode of action of Cr(VI)-induced intestinal tumors in rodents. Society of Toxicology 57th Annual Meeting, San Antonio, TX, March 2018.

Thompson CT, Suh M, Chappell G, Borghoff S, Ellis-Hutchings, R, Wiench, K, Finch, L, Proctor DM. 2018. Assessment of the mode of action underlying development of forestomach tumors in rodents following oral exposure to ethyl acrylate and relevance to humans. Regul Toxicol Pharmacol 96:178–189; doi: 10.1016/j.yrtph.2018.05.006.

Thompson CM, Suh M, Proctor DM, Haws LC, Harris MA. 2017. Ten factors for considering the mode of action of Cr(VI)-induced gastrointestinal tumors in rodents. Mutat Res 823(Nov):45-57; doi: 10.1016/j.mrgentox.2017.08.004.

Rager JE, Thompson CM, Ring C, Fry RC, Harris MA. Integration of transcriptomics and high-throughput screening predictions with robust in vivo data to inform hexavalent chromium mode of action. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Thompson CM, Bichteler A, Rager JE, Suh M, Proctor DM, Haws LC, Harris MA. 2016. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium. Mut Res/Genet Toxicol Environ Mutagen 800-801(April):28-34; doi: 10.1016/j.mrgentox.2016.01.008.

Proctor DM, Suh M, Campleman SL, Thompson CM. 2014. Assessment of the mode of action for hexavalent chromium-induced lung cancer following inhalation exposures. Toxicol 325(Nov):160-179; doi: 10.1016/j.tox.2014.08.009.

Thompson CM, Proctor DM, Suh M, Haws LC, Kirman CR, Harris MA. 2013. Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans. Crit Rev Toxicol 43(3):244-274; doi: 10.3109/10408444.2013.768596.

Proctor DM, Suh M, Thompson CM, Harris MA. 2013. Mode of action evaluation for hexavalent chromium-induced lung cancer. Presented at Society of Toxicology 52nd Annual Meeting, March 10-14, San Antonio, TX.

Thompson CM, Proctor DM, Suh M, Haws LC, Hebert CD, Mann JF, Shertzer HG, Hixon JG,Harris MA. 2012. Comparison of the effects of hexavalent chromium in the alimentary canal of F344 rats and B6C3F1 mice following exposure in drinking water: Implications for carcinogenic modes of action. Toxicol Sci 125(1):79-90; doi: 10.1093/toxsci/kfr280.